This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why
by Zacks Equity Research
Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.
Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi
by Zacks Equity Research
J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.
Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer
by Zacks Equity Research
Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.
Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study
by Zacks Equity Research
Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.
Zacks.com featured highlights Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis
by Zacks Equity Research
Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis have been highlighted in this Screen of The Week article.
AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study
by Zacks Equity Research
AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.
These 5 Price-to-Sales Stocks Can Be Rewarding Investments
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, SKM, PBF, ARW and NVS hold promise.
NVS vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
After Plunging -7.17% in 4 Weeks, Here's Why the Trend Might Reverse for Novartis (NVS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Novartis (NVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak
by Zacks Equity Research
Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.
Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.
Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA
by Zacks Equity Research
The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.
Incyte (INCY) Reports Positive Long-Term Data From HS Study
by Zacks Equity Research
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy
by Zacks Equity Research
Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Weibo and Viasat have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Weibo and Viasat are part of the Zacks Bull and Bear of the Day article.
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.
Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
by Zacks Equity Research
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.